The GUF1 Knockout A-549 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout population derived from the human A-549 lung adenocarcinoma epithelial cell line, engineered for loss-of-function studies of the GUF1 gene. This heterogeneous cell pool enables functional investigation of GUF1-dependent mitochondrial translation defects without clonal selection effects.
A-549 cells, isolated from the lung carcinoma of a 58-year-old Caucasian male, exhibit adherent epithelial morphology and serve as a established model for non-small cell lung cancer (NSCLC). Their widespread use in cancer research, including studies of metabolic plasticity and drug response, provides a well-characterized background for CRISPR-mediated gene disruption and subsequent functional assays.
GUF1 encodes a mitochondrial translation elongation factor essential for ribosome recycling and quality control of mitochondrial protein synthesis. GUF1 operates downstream of mTOR signaling and NRF1/TFAM-driven mitochondrial biogenesis programs, interacting with mitochondrial ribosomal subunits (MRPL, MRPS) and factors such as TUFM and mtRF1. Disruption of GUF1 impairs translation elongation, leading to reduced synthesis of mtDNA-encoded OXPHOS subunits like MT-CO1, MT-ND1, and MT-ATP6, and consequent oxidative phosphorylation deficiency, ATP depletion, and increased mitochondrial ROS. These defects trigger compensatory mitochondrial stress responses and disrupt respiratory chain complex assembly.
In the A-549 NSCLC context, GUF1 knockout reveals critical dependencies on mitochondrial translation for cancer cell metabolism and survival. The polyclonal population captures heterogeneous editing outcomes, making it suitable for pooled screens and analysis of how mitochondrial dysfunction influences tumorigenic properties. This model is relevant for studying combined oxidative phosphorylation deficiency, Leigh syndrome, and neurodevelopmental disorders linked to mitochondrial translation, while also providing a platform to test interventions that modulate mitochondrial function in a cancer-relevant background.
Key applications include drug screening for mitochondrial disease therapeutics, investigating OXPHOS assembly dynamics, and profiling metabolic responses using assays such as western blotting for OXPHOS subunits, puromycin incorporation to monitor mitochondrial translation, Seahorse-based oxygen consumption rate measurements, ATP luciferase assays, and TMRM staining for mitochondrial membrane potential. Additionally, galactose medium viability assays can assess OXPHOS dependence. These polyclonal knockout cells thus support diverse studies in mitochondrial biology and cancer metabolism. For further information, please contact Ascent Research.
